ambisome 50 mg pulver zur herstellung einer infusionslösung
haemato pharm gmbh - amphotericin b -
daunoxome 2 mg/ml, konzentrat zur herstellung einer infusionslösung
intergal pharma limited (8144431) - daunorubicinhydrochlorid - konzentrat zur herstellung einer infusionslösung - teil 1 - konzentrat zur herstellung einer infusionslösung; daunorubicinhydrochlorid (07163) 53,46 milligramm
retrovir 100mg hartkapseln
viiv healthcare b.v. (8182271) - zidovudin - hartkapsel - zidovudin (24191) 100 milligramm
retrovir i.v. 10mg/ml konzentrat zur herstellung einer infusionslösung
viiv healthcare b.v. (8182271) - zidovudin - konzentrat zur herstellung einer infusionslösung - zidovudin (24191) 200 milligramm
retrovir 250mg hartkapseln
viiv healthcare b.v. (8182271) - zidovudin - hartkapsel - zidovudin (24191) 250 milligramm
retrovir 300mg filmtabletten
viiv healthcare uk limited (8130038) - zidovudin - filmtablette - zidovudin (24191) 300 milligramm
retrovir 100mg/10ml lösung zum einnehmen
viiv healthcare b.v. (8182271) - zidovudin - lösung zum einnehmen - zidovudin (24191) 50 milligramm
tenofovirdisoproxil stada 245 mg filmtabletten
stada arzneimittel gmbh - tenofovir disoproxil succinat -
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastische mittel - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymphom, mantelzell - antineoplastische mittel - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).